Antifungal agents in neonatal systemic candidiasis

Antifungal agents in neonatal systemic candidiasis.

Neonatal systemic candidiasis is increasingly being recognized as a cause of septicemia in the neonatal intensive care unit (2, 19, 26, 36, 59). Predisposing factors for candidemia and subsequently invasive infections include prematurity, prolonged exposure to broad-spectrum antibiotics, the use of intravenous fat emulsions, the presence of necrotizing enterocolitis, prolonged intravascular cat...

Systemic neonatal candidiasis.

Forty-five cases of systemic neonatal candidiasis were diagnosed over a 9-year period in a neonatal intensive care unit; 42 infants weighted less than 1.5 kg. All had been very ill with preceding bacterial sepsis and other complications of low birthweight. Where treatment was instituted the mortality was low (4 out of 39 dying) and complications of treatment were transitory. We therefore recomm...

Neonatal systemic candidiasis.

Neonatal systemic candidiasis.

Ten babies who required neonatal intensive care developed systemic candidiasis. Eight were extremely preterm (28 weeks' gestation or less) and all received prolonged ventilation, multiple courses of broad spectrum antibiotics, and intravenous hyperalimentation. Diagnosis was established by culture of yeasts from suprapubic urine specimens; venous blood cultures proved unreliable. Initial treatm...

Systemic Antifungal Agents

Systemic antifungal agents and their use for the therapy of invasive mycoses are discussed in this chapter. Many of these agents can also be used to treat the mucocutaneous forms of candidiasis, but those uses are discussed in detail in Chapter 257 and thus are mentioned only in passing here. Similarly, the therapy of the various forms of tinea and onychomycosis with topical agents or systemic ...